Abstract
The shortage of enzyme for treatment of Fabry disease has caused anxiety among patients, physicians and governments. Following a request from the European Medicines Agency, consensus was reached on the temporary prioritization of patients for treatment based on disease severity and potential reversibility. Advice on follow-up of patients was agreed upon. This consensus is proposed to support the temporary guidelines issued throughout the period of ERT shortage, which will most likely last until April 2011
| Original language | English |
|---|---|
| Pages (from-to) | 99-102 |
| Journal | Molecular genetics and metabolism |
| Volume | 102 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
Dive into the research topics of 'Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver